Zoom; or, Obsolescence

2021 ◽  
Vol 65 (3) ◽  
pp. 181-200
Author(s):  
W.B. Worthen

The signal modality of theatrical production during the pandemic crisis of 2020–21 has been Zoom theatre. While Zoom theatre responds to public health concerns regarding virus transmission, it also articulates a vision of performance at the intersection of the public and the private, at the juncture between theatre and electronic media, and as a representation of theatre as a humanizing technology. Theatre has suggestively foregrounded new technologies under the sign of obsolescence, and in the affective register of nostalgia.

Cureus ◽  
2019 ◽  
Author(s):  
Valeriy Zvonarev ◽  
Tolulope A Fatuki ◽  
Polina Tregubenko

Author(s):  
Laura Mitchem ◽  
Henrietta Harrison ◽  
Alex G. Stewart

Fires can cause significant health concerns within local communities impacted by any associated smoke plume. This chapter discusses the potential public health concerns associated with fires, in particular fires at waste-processing installations. Using an example scenario, actions to be undertaken throughout the incident response, from initial acute phase to recovery, are considered, along with health concerns and fears, real or perceived, involvement of asbestos-contaminant material, multi-agency communication mechanisms, and potential issues associated with long-running fires. The multi-agency mechanisms for response are detailed, including the various coordinating groups (strategic, tactical, recovery coordinating groups (SCG, TCG, RCG, respectively), and expert cells (scientific and technical advisor cell, air quality cell (AQC)). Key points to note in the incident response include concerns raised by the local population, typical health effects associated with exposure to a smoke plume, and tools that support the response to the incident and the public health risk assessment.


2014 ◽  
Vol 20 (1) ◽  
Author(s):  
Dushon DeVere Riley ◽  
Mark Cochran

Neurodegenerative diseases are one of the leading public health challenges of the next 50 years. Pharmaceutical therapies have traditionally targeted the later stages of neurodegenerative diseases; however, this strategy - as the recent failures of clinical trials for Alzheimer’s drugs have highlighted - has been unsuccessful. Venture capital has underperformed as well during this time, as many new companies have been unable to maintain growth once they reach the public market and have produced less than desirable returns. As a result, venture capitalists have opted for later-stage financing. Nevertheless, new technologies are being developed to answer the question of how to best address neurodegeneration. New tools of detection will allow for much earlier diagnosis and a much greater chance of discovering and applying effective treatments. Realizing that genetic knowledge is insufficient to produce innovative treatments for neurodegenerative diseases, scientists have begun to apply the genetic knowledge attained towards a future of individualized treatments. As these new tools of detection converge with an increased ability to create very precise individual solutions, the risk of successful future investments should come down and provide the potential for outsized returns that have traditionally governed the venture capital financial model.


2019 ◽  
Vol 41 (4) ◽  
pp. 21-25
Author(s):  
Christine L. Arazan ◽  
Brianna A. Barrios ◽  
Meredith S. Brown ◽  
Natalia O. Dmitrieva

Limited research exists concerning measurement issues of health-related constructs among those incarcerated in American jails. This gap in the literature impedes research on health outcomes and health care access among jailed populations and may render the public health concerns of jailed populations hidden from societal view. The current article examines a research team's experience in conducting a related study (see Trotter et al. 2018) by highlighting the methodological limitations and opportunities faced during the study and provides suggestions for future research. The manuscript provides future researchers with a foundation for implementing health-focused studies within a jail, with special attention paid to the obstacles the research team overcame.


2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Jay Huang ◽  
Wayne Loschen

ObjectiveThe objective of this presentation is to explore emerging technologies and how they will impact the public health field. New technologies such as blockchain, artificial intelligence (AI), and the Internet of Things (IoT) will likely be incorporated into epidemiological methods and processes. This presentation will provide an overview of these technologies and focus on how they may impact public health surveillance in the future.IntroductionWith the increase in the amount of public health data along with the growth of public health informatics, it is important for epidemiologists to understand the current trends in technology and the impact they may have in the field. Because it is unfeasible for public health professionals to be an expert in every emerging technology, this presentation seeks to provide them with a better understanding of how emerging technologies may impact the field and the level of expertise required to realize benefits from the new technologies. Furthermore, understanding the capabilities provided by emerging technologies may guide future training and continuing education for public health professionals.MethodsAnalysis of current capabilities and potential advances in emerging technologies such as blockchain, AI, and IoT were performed by reviewing articles and whitepapers. In addition to a literature review, interviews will be performed with public health experts to determine how the emerging technologies align with current practices and the extent to which they may solve existing public health surveillance challenges.ResultsThe literature review revealed many emerging technologies and potential applications in the public health field, including:BlockchainBlockchains can serve as electronic health information exchanges that hold the metadata and access information for patient electronic health records (EHRs).1 These systems can ensure data privacy protections while also facilitate relevant data sharing from EHRs to disease surveillance systems. Furthermore, blockchain technology can be used in food supply chain management systems. During food contamination events, epidemiologists can trace through the blockchain to identify possible sources of the contamination.2AIAI can be used to improve the prediction and detection capabilities of disease surveillance systems. Machine learning algorithms can reveal patterns in the data and enable faster anomaly detection. Furthermore, machine learning models can be trained on data to create predictive models.IoTUrban IoT systems can monitor environmental indices including water and air quality, energy consumption, waste management, and traffic congestion in smart cities.3 The data collected from such systems can be incorporated into more comprehensive disease surveillance systems and assist epidemiologists in better understanding populations and environmental risk factors.We will analyze and discuss such prospective applications with public health professionals to determine their potential impact on public health processes and practices in the next one, five, and ten years.ConclusionsBlockchain, AI, IoT and other emerging technologies have applications in public health surveillance and impact the field to varying degrees. In addition to technological advances, there will be barriers to adoption that must be overcome before the value provided by the technologies can be realized. Many new technologies will require significant collaboration between public health departments, healthcare providers, and other partners to successfully incorporate the technologies into epidemiological processes. These collaborations include forming consortiums to exchange data in a blockchain and working with IoT providers for data access. Some technologies will require public health professionals to obtain additional training before they can take full advantage of the capabilities provided, while other technologies may be implemented by external partners allowing epidemiologists to utilize the new capabilities without the need to completely understand the underlying concepts. As emerging technologies are introduced into the public health field, a strong understanding of their capabilities and suitable applications will allow public health professionals to fully capture the benefits provided by the new technologies.References1. Ekblaw A, Azaria A, Halamka JD, Lippman A. A Case Study for Blockchain in Healthcare:“MedRec” prototype for electronic health records and medical research data. InProceedings of IEEE open & big data conference 2016 Aug 22 (Vol. 13, p. 13).2. Yiannas F. A New Era of Food Transparency Powered by Blockchain. Innovations: Technology, Governance, Globalization. 2018 Jul;12(1-2):46-56.3. Zanella A, Bui N, Castellani A, Vangelista L, Zorzi M. Internet of things for smart cities. IEEE Internet of Things Journal. 2014 Feb 14;1(1):22-32.


2021 ◽  
Author(s):  
Domenico Martinelli ◽  
Francesca Fortunato ◽  
Sara Mazzilli ◽  
Lucia Bisceglia ◽  
Pier Luigi Lopalco ◽  
...  

Abstract Early in the COVID-19 pandemic, asymptomatic transmission represented an important challenge for controlling the spread of SARS-CoV-2 through the traditional public health strategies. Further understanding of the contribution of asymptomatic infections to SARS-CoV-2 transmission has been of crucial importance for pandemic control. We conducted a retrospective epidemiological study to characterize asymptomatic COVID-19 cases occurred in the Apulia region, Italy, during the first epidemic wave of COVID-19 outbreak (February 29 - July 7, 2020). We analyzed data collected in a regional platform developed to manage surveillance activities, namely investigation and follow-up of cases and contacts, contact tracing, laboratory and clinical data collection. We included all asymptomatic cases that were laboratory-confirmed during the appropriate follow-up, defined as persons infected with SARS-CoV-2 who did not develop symptoms/clinical signs of the disease. Between February 29 and July 7, 2020, a total of 4,536 cases were diagnosed with COVID-19 among 193,757 tests performed. The group of persons with asymptomatic SARS-CoV-2 infection consisted of 903 cases; the asymptomatic proportion was 19.9% (95%CI: 18.8-21.1%); this decreased with increasing age (OR: 0.89, 95%CI: 0.83-0.96; p=0.001), in individuals with underlying comorbidities (OR: 0.55, 95%CI: 0.41-0.73; p<0.001), and in males (OR: 0.69, 95%CI: 0.54-0.87; p=0.002). The median asymptomatic SARS-CoV-2 RNA positive period was 19 days (IQR: 14-31) and the cumulative proportion of persons with resolution of infection 14 days after the first positive PCR test was 74%. As the public health community is debating the question of whether asymptomatic and late spreaders could sustain virus transmission in the communities, such cases present unique opportunities to gain insight into SARS-CoV-2 adaptation to human host. This has important implications for future COVID-19 surveillance and prevention.


2018 ◽  
Vol 34 (S1) ◽  
pp. 85-86
Author(s):  
Ana Paula B S Etges ◽  
Priscila da Rosa ◽  
Regina K Notti ◽  
Luciane N Cruz ◽  
Madeni Doebber ◽  
...  

Introduction:Extracorporeal circulatory membrane oxygenation (ECMO) is a technology that allows recovery of adults in cardiorespiratory failure with encouraging results, but is not available in the Brazilian universal public health system (SUS) due to high implementation costs. Time-driven activity based costing (TDABC) is applied to measure processes in an economic perspective by identifying opportunities to make processes more efficient through the reduction of resources used in each activity. The literature has explored the use of TDABC to measure costs related with clinical procedures and technologies in microcosting studies, identifying opportunities to improve the process by making it more efficient. This research measures the real costs to implement ECMO in Brazil to compare with the current public reimbursement system.Methods:This study applied TDABC using data from 6 patients to measure costs of ECMO intervention considering the public perspective in Brazil. In sequence, standard price payed by SUS was used to estimate the current reimbursement amount received by the hospital for ECMO procedure. Cost variable analysis was conducted to understand when and how patients receiving ECMO are using hospital resources. Cost data were collected from an academic public hospital using an average of 18 months (2016–2017) for the department costs.Results:The real average cost was USD 128,923. Most significant resource costs was medical staff, particularly for the three survivor patients, and the ECMO equipment presented the second highest cost. ECMO activities were separated into: before implantation of ECMO, period using ECMO, intensive care post-ECMO and rehabilitation, being the period where ECMO is the most expensive, particularly in nurse and physician costs. The SUS average was USD 31,437, which shows a difference of USD 97,485 between the real ECMO cost and the public reimbursement in Brazil.Conclusions:A critical element of the propagation of ECMO in Brazil and its reimbursement by public health system is the high cost and out-of-date standard payments by the Ministry of Health. Effort to implement a trustworthy method to guide decisions of SUS for the adoption and financing new technologies is essential to contribute to the optimization of public health policies in a country with a universal health system and limited resources dedicated to health sectors.


2016 ◽  
Vol 9 (6) ◽  
pp. 441
Author(s):  
SaurabhRamBihariLal Shrivastava ◽  
PrateekSaurabh Shrivastava ◽  
Jegadeesh Ramasamy

Sign in / Sign up

Export Citation Format

Share Document